Entero Therapeutics, Inc. (NASDAQ: ENTO) is a publicly listed company on Nasdaq. Entero Therapeutics is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following completion of the GRID AI acquisition, ENTO intends to continue these prior operations and to operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.
Entero Therapeutics, Inc.
Disclaimer: All stock information on InvestorNews.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.